{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:40:14Z","timestamp":1792521614019,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04581-5","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:56:32Z","timestamp":1792266992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-related local complications as a major contributor to mortality after definitive radiotherapy for unresectable extrahepatic bile duct cancer"],"prefix":"10.1007","author":[{"given":"Ye Jin","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1088-0174","authenticated-orcid":false,"given":"Jin-hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"2","key":"4581_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"4581_CR2","unstructured":"National Comprehensive Cancer Network. Biliary tract cancers (version 2.2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf. Accessed 2 Jul 2025."},{"issue":"4","key":"4581_CR3","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0360-3016(02)02845-6","volume":"53","author":"CH Crane","year":"2002","unstructured":"Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):969\u201374. https:\/\/doi.org\/10.1016\/S0360-3016(02)02845-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4581_CR4","first-page":"265","volume":"42","author":"H Ohnishi","year":"1995","unstructured":"Ohnishi H, Asada M, Shichijo Y, Iijima N, Itobayashi E, Shimura K, et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology. 1995;42(3):265\u20138.","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"4581_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.coc.0000217829.77404.22","volume":"29","author":"JY Park","year":"2006","unstructured":"Park JY, Park SW, Chung JB, Seong J, Kim KS, Lee WJ, et al. Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. Am J Clin Oncol. 2006;29(3):240\u20135. https:\/\/doi.org\/10.1097\/01.coc.0000217829.77404.22.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"4581_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","volume":"34","author":"R Tao","year":"2016","unstructured":"Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2016;34(3):219\u201326. https:\/\/doi.org\/10.1200\/JCO.2015.61.3778.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4581_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","volume":"195","author":"J Lee","year":"2019","unstructured":"Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol. 2019;195(2):93\u2013102. https:\/\/doi.org\/10.1007\/s00066-018-1367-2.","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"4581_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.7150\/jca.13032","volume":"6","author":"A Mahadevan","year":"2015","unstructured":"Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, et al. Stereotactic body radiotherapy for intrahepatic and hilar cholangiocarcinoma. J Cancer. 2015;6(11):1099\u2013104. https:\/\/doi.org\/10.7150\/jca.13032.","journal-title":"J Cancer"},{"issue":"1","key":"4581_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/cco.2019.12.05","volume":"9","author":"S Avila","year":"2020","unstructured":"Avila S, Smani DA, Koay EJ. Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma. Chin Clin Oncol. 2020;9(1):10. https:\/\/doi.org\/10.21037\/cco.2019.12.05.","journal-title":"Chin Clin Oncol"},{"issue":"10","key":"4581_CR10","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1002\/cam4.1734","volume":"7","author":"D Elganainy","year":"2018","unstructured":"Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, et al. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018;7(10):4880\u201392. https:\/\/doi.org\/10.1002\/cam4.1734.","journal-title":"Cancer Med"},{"issue":"3","key":"4581_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000530134","volume":"12","author":"B De","year":"2023","unstructured":"De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, et al. Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases. Liver Cancer (Basel). 2023;12(3):198\u2013208. https:\/\/doi.org\/10.1159\/000530134.","journal-title":"Liver Cancer (Basel)"},{"issue":"8","key":"4581_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/cncr.30488","volume":"123","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, et al. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients. Cancer (Basel). 2017;123(8):1354\u201362. https:\/\/doi.org\/10.1002\/cncr.30488.","journal-title":"Cancer (Basel)"},{"issue":"23","key":"4581_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70196","volume":"13","author":"S Bisello","year":"2024","unstructured":"Bisello S, Malizia C, Mammini F, Galietta E, Medici F, Mattiucci GC, et al. Chemoradiation of locally advanced biliary cancer: a PRISMA-compliant systematic review. Cancer Med. 2024;13(23):e70196. https:\/\/doi.org\/10.1002\/cam4.70196.","journal-title":"Cancer Med"},{"issue":"16","key":"4581_CR14","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","volume":"42","author":"MA Hawkins","year":"2024","unstructured":"Hawkins MA, Valle JW, Wasan HS, Harrison M, Morement H, Manoharan P, et al. Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced cholangiocarcinoma (ABC-07): results from a randomized phase II trial [abstract]. J Clin Oncol. 2024;42(16):4006. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4006.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4581_CR15","first-page":"737","volume":"36","author":"R Autorino","year":"2016","unstructured":"Autorino R, Mattiucci GC, Ardito F, Balducci M, Deodato F, Macchia G, et al. Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: long-term results of a phase II study. Anticancer Res. 2016;36(2):737\u201340.","journal-title":"Anticancer Res"},{"issue":"3","key":"4581_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ijrobp.2010.06.018","volume":"81","author":"AP Ghafoori","year":"2011","unstructured":"Ghafoori AP, Nelson JW, Willett CG, Chino J, Tyler DS, Hurwitz HI, et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2011;81(3):654\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.018.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4581_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase III study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"4581_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled phase III trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"4","key":"4581_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2025.43.4_suppl.570","volume":"43","author":"M Kuang","year":"2025","unstructured":"Kuang M, Peng Z, Shen SL, Chen S, Xiao H. Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer (ACCORD trial) [abstract]. J Clin Oncol. 2025;43(4):570. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.570.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04581-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:01:59Z","timestamp":1792519319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04581-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":19,"alternative-id":["4581"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04581-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the 1964 Helsinki Declaration and its later amendments and was approved by the Institutional Review Board of Asan Medical Center (approval number: 2020\u20131782). Informed consent was waived owing to the retrospective design.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}